ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselBioVersys AG
BioVersys AG Logo
Verified· 3 sources

BioVersys AG

Summary

About the company

The core activity of Bioversys AG is the development and manufacture of pharmaceuticals, particularly in the field of antibiotic research and the development of therapeutics for various diseases. The company is engaged in the research and development of small molecules, peptides and therapeutic polymers and has experts in the fields of medicinal chemistry, CMC (Chemistry, Manufacturing, Control) and biotechnology on its team.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered6
Drug research and development against antimicrobial resistance
Development of novel antibiotics with new mechanisms of action against antibiotic-resistant pathogens, in particular for severe hospital infections and other priority pathogens.
Drug research and development against tuberculosis
Development of a new anti-TB drug substance with a unique mechanism of action to potentiate ethionamide, including clinical testing in MDR-TB and TB meningitis.
Research and development of anti-virulence agents
Development of a first-in-class anti-virulence candidate against Staphylococcus aureus, including MRSA, for skin infections, pneumonia and atopic dermatitis.
Research and development against non-tuberculous mycobacterial infections
Development of a pipeline of compounds against NTM infections based on the company's proprietary ansamycin platform and the bacterial RNA polymerase target.
Drug discovery for ESKAPE pathogens
Development of small-molecule programs against important ESKAPE pathogens and other priority bacterial pathogens.
Press

Media

November 10, 2025Media
Wellcome awards CHF 14 million for BioVersys’ BV100 Phase 2b study
startupticker.ch

Knowledge

No knowledge articles yet

Once BioVersys AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

BioVersys AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank BioVersys AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of BioVersys AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hochbergerstrasse 60C
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-114.512.761
Founded
2008 · 18 years
Last commercial register change
June 26, 2026
Employees
21 to 50

Similar companies

NA
NBE-Therapeutics AG
Basel
FT
FoRx Therapeutics AG
Basel
EP
Eumedica Pharmaceuticals AG
Basel
3B
3T Biosciences Europe GmbH
Basel